New Data from the DanGer Shock Randomized Control Trial, Published in The New England Journal of Medicine, Confirms the Long-Term Survival Benefit of the Impella CP Heart Pump
(NYSE:JNJ) MADRID, Aug. 31, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) – Late breaking clinical science data, presented at the European Society of Cardiology (ESC) Congress today and simultaneously published in the New England Journal of Medicine (NEJM), finds at up to 10 years, when...
Related Questions
How will the new long‑term survival data for the Impella CP affect Johnson & Johnson’s cardiovascular device revenue forecasts and earnings guidance?
What pricing, reimbursement, and adoption hurdles could limit the commercial upside of the Impella CP compared with competing mechanical circulatory support devices?
Will the positive trial results trigger any regulatory approvals, insurance coverage changes, or partnership activity that could drive a material change in JNJ’s valuation?